Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Reinforcement Schedules01:24

Reinforcement Schedules

479
Positive reinforcement is a powerful method for teaching new behaviors to both animals and humans. B.F. Skinner demonstrated this with his experiments using rats in a Skinner box. When a rat pressed a lever, it received a food pellet. This immediate reward encouraged the rat to repeat the behavior. This method, where a reward follows every instance of the behavior, is known as continuous reinforcement. It is highly effective for establishing new behaviors quickly.
Once a behavior is learned,...
479
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

220
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
220
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

217
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
217
Clinical Trials01:16

Clinical Trials

10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

A randomized Bayesian phase I-II dose optimization design for combination cancer therapies with progression-free survival end point.

BMC medical research methodology·2025
Same author

A robust Bayesian dose optimization design with backfill and randomization for phase I/II clinical trials.

Statistical methods in medical research·2025
Same author

A model-free phase I/II dose optimization design for immunotherapy trials.

Statistical methods in medical research·2025
Same author

A Phase I Dose-Finding Design Incorporating Intra-Patient Dose Escalation.

Pharmaceutical statistics·2024
Same author

A Bayesian Dynamic Model-Based Adaptive Design for Oncology Dose Optimization in Phase I/II Clinical Trials.

Pharmaceutical statistics·2024
Same author

Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies.

Clinical trials (London, England)·2024

関連する実験動画

Updated: Jan 24, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K

免疫療法試験のためのバイオマーカーベースの用量スケジュール最適化デザイン

Yingjie Qiu1,2, Yan Han3, Beibei Guo4

  • 1Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Statistics in medicine
|January 23, 2026
PubMed
まとめ

免疫療法の薬物用量とスケジュールを最適化することは非常に重要です。この研究では、バイオマーカーサブグループ、免疫応答、有効性、および毒性データを使用して、個別化された戦略を提案し、臨床試験の意思決定を改善します。

キーワード:
ベイジアン適応デザインバイオマーカー免疫療法最適治療レジメン第I/II相試験リスクとベネフィットのトレードオフサブグループ

さらに関連する動画

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.3K
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.6K

関連する実験動画

Last Updated: Jan 24, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.3K
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

1.6K

科学分野:

  • 免疫療法
  • 臨床試験デザイン
  • 生物統計学

背景:

  • 免疫応答を調節することにより、薬物用量とスケジュールは免疫療法の有効性に大きく影響します。
  • 免疫応答測定を臨床試験に統合することは、有効性と毒性との関連があるため、意思決定に役立ちます。
  • バイオマーカーデータは、治療効果が改善された患者サブグループを特定できます。

主な方法:

  • 免疫応答、毒性、および有効性を同時に評価するために、共同モデリングフレームワークが開発されました。
  • 効用関数は、患者固有のリスクとベネフィットのトレードオフを捉えるために引き出されました。
  • 初期段階の試験における少数のサンプルサイズを処理するために、簡潔でありながら柔軟なモデルが採用されました。

結論:

  • 新しい用量スケジュール最適化戦略は、免疫療法臨床試験のデザインを強化します。
  • バイオマーカーサブグループと統合アウトカムモデリングに基づいた治療の調整は、リスクとベネフィットの評価を改善します。
  • 提案された方法は、サンプルサイズが限られた初期段階の試験に適しています。